Pactimibe sulfate

Phase 2/3Terminated

0 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Atherosclerosis

Conditions

Atherosclerosis, Heterozygous Familial Hypercholesterolemia

Trial Timeline

Feb 1, 2004 → Mar 1, 2006

NCT ID

NCT00151788

About Pactimibe sulfate

Pactimibe sulfate is a phase 2/3 stage product being developed by Daiichi Sankyo for Atherosclerosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00151788. Target conditions include Atherosclerosis, Heterozygous Familial Hypercholesterolemia.

What happened to similar drugs?

13 of 20 similar drugs in Atherosclerosis were approved

Approved (13) Terminated (3) Active (6)

✅Rosuvastatin + placebo + aspirin + placeboAstraZenecaApproved

✅Rosuvastatin + PlaceboAstraZenecaApproved

✅Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mgAstraZenecaApproved

✅Niacin/simvastatin compared to simvastatin alone at 2 dosesMerckApproved

✅Ezetimibe + PlaceboMerckApproved

✅Simvastatin or Atorvastatin + Enalapril + Aspirin or clopidogrel + RimonabantPfizerApproved

✅AtorvastatinPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00151788	Phase 2/3	Terminated	Feb 1, 2004	Mar 1, 2006	Atherosclerosis

Competing Products

20 competing products in Atherosclerosis

See all competitors

Product	Company	Stage	Hype Score
Orforglipron + Placebo	Eli Lilly	Phase 3	47
Olmesartan medoxomil + Placebo	Daiichi Sankyo	Phase 3	40
Pactimibe	Daiichi Sankyo	Phase 2	35
Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin	Daiichi Sankyo	Phase 3	47
Micronized 17B-estradiol	Johnson & Johnson	Phase 2/3	38
Rosuvastatin + placebo + aspirin + placebo	AstraZeneca	Approved	43
Rosuvastatin + Placebo	AstraZeneca	Approved	35
rosuvastatin + placebo	AstraZeneca	Phase 1	29
Rosuvastatin + Placebo	AstraZeneca	Phase 1	29
Rosuvastatin + Atorvastatin	AstraZeneca	Phase 3	40
Rosuvastatin + Placebo	AstraZeneca	Phase 3	40
Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mg	AstraZeneca	Approved	39
Vorapaxar + Placebo	Merck	Phase 3	40
Vorapaxar + Placebo + Aspirin + Clopidogrel	Merck	Phase 2	35
Niacin/simvastatin compared to simvastatin alone at 2 doses	Merck	Approved	43
lovastatin	Merck	Phase 2/3	38
Ezetimibe + Placebo	Merck	Approved	43
Vorapaxar + Placebo	Merck	Phase 3	32
Niaspan	Merck	Pre-clinical	22
MK0633	Merck	Phase 2	35